DSGN Q1 2023 Earnings — Design Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DSGNDesign Therapeutics, Inc.

$569M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$19M

EPS (Diluted)

$-0.30

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$325M

Total Liabilities

$12M

Stockholders' Equity

$313M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$13M	-61.9%
Net Income	-$19M	-$13M	-45.5%